Market Exclusive

Oramed Gets Buy Rating From FBR & Co. Target: $20

oramed ormporamed ormp

Oramed Pharmaceuticals, Inc.(NASDAQ:ORMP) just picked up a buy rating form FBR & Co. the development stage biotech, which is working on a highly anticipated oral administration version of insulin, currently trades at a little over $8 a share, for a market capitalization of $108 million. Under the buy thesis outlined by FBR & Co, the company has a target price of $20.

You can read the full report here.

Here are some of the highlights:

Here’s the report’s investment thesis:

Given its focus on developing orally administered peptides that are currently largely available as injectables, we view Oramed as owning platform technology with a strong patent estate. We believe the data for both ORMD-0801 and ORMD-0901 are compelling and remain buyers of the stock, especially at current levels.

Again, check out the full report here.

Exit mobile version